Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 27 06 2023
accepted: 11 08 2023
medline: 18 9 2023
pubmed: 15 9 2023
entrez: 15 9 2023
Statut: epublish

Résumé

Family studies of antiviral immunity provide an opportunity to assess virus-specific immunity in infected and highly exposed individuals, as well as to examine the dynamics of viral infection within families. Transmission of SARS-CoV-2 between family members represented a major route for viral spread during the early stages of the pandemic, due to the nature of SARS-CoV-2 transmission through close contacts. Here, humoral and cellular immunity is explored in 264 SARS-CoV-2 infected, exposed or unexposed individuals from 81 families in the United Kingdom sampled in the winter of 2020 before widespread vaccination and infection. We describe robust cellular and humoral immunity into COVID-19 convalescence, albeit with marked heterogeneity between families and between individuals. T-cell response magnitude is associated with male sex and older age by multiple linear regression. SARS-CoV-2-specific T-cell responses in seronegative individuals are widespread, particularly in adults and in individuals exposed to SARS-CoV-2 through an infected family member. The magnitude of this response is associated with the number of seropositive family members, with a greater number of seropositive individuals within a family leading to stronger T-cell immunity in seronegative individuals. These results support a model whereby exposure to SARS-CoV-2 promotes T-cell immunity in the absence of an antibody response. The source of these seronegative T-cell responses to SARS-CoV-2 has been suggested as cross-reactive immunity to endemic coronaviruses that is expanded upon SARS-CoV-2 exposure. However, in this study, no association between HCoV-specific immunity and seronegative T-cell immunity to SARS-CoV-2 is identified, suggesting that de novo T-cell immunity may be generated in seronegative SARS-CoV-2 exposed individuals.

Identifiants

pubmed: 37711627
doi: 10.3389/fimmu.2023.1248658
pmc: PMC10497976
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1248658

Subventions

Organisme : Department of Health
ID : NIHR300791
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 222426/Z/21/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W02067X/1
Pays : United Kingdom

Informations de copyright

Copyright © 2023 Jay, Adland, Csala, Dold, Edmans, Hackstein, Jamsen, Lim, Longet, Ogbe, Sampson, Skelly, Spiller, Stafford, Thompson, Turtle, Barnes, Dunachie, Carroll, Klenerman, Conlon, Goulder and Jones.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
Virology. 2003 Sep 30;314(2):601-16
pubmed: 14554088
J Infect Dis. 2020 Jun 11;221(12):1948-1952
pubmed: 32319519
Euro Surveill. 2020 Oct;25(42):
pubmed: 33094713
Pediatr Allergy Immunol. 2022 Jul;33(7):
pubmed: 35871459
AIDS. 1994 Oct;8(10):1391-5
pubmed: 7818809
Arch Dis Child. 2020 Dec 1;:
pubmed: 33262177
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):446-450
pubmed: 32298246
Lancet Infect Dis. 2020 Apr;20(4):410-411
pubmed: 32087116
J Infect Dis. 2011 Mar 15;203(6):847-53
pubmed: 21343150
Nat Commun. 2021 Nov 25;12(1):6844
pubmed: 34824230
Front Immunol. 2020 Mar 25;11:517
pubmed: 32269575
J Infect Dis. 2021 Jul 2;224(1):70-80
pubmed: 33822097
Nat Commun. 2021 May 11;12(1):2670
pubmed: 33976165
Nat Commun. 2021 Apr 6;12(1):2055
pubmed: 33824342
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261718
Nat Commun. 2022 Jan 10;13(1):80
pubmed: 35013199
Mech Ageing Dev. 2022 Jun;204:111672
pubmed: 35378106
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Nat Rev Immunol. 2020 Jul;20(7):442-447
pubmed: 32528136
Front Immunol. 2023 Jan 26;14:1092910
pubmed: 36776841
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427

Auteurs

Cecilia Jay (C)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Emily Adland (E)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Anna Csala (A)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Christina Dold (C)

Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.

Matthew Edmans (M)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Carl-Philipp Hackstein (CP)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Anni Jamsen (A)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Nicholas Lim (N)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Stephanie Longet (S)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Ane Ogbe (A)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Oliver Sampson (O)

Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom.

Donal Skelly (D)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Oxford University Hospitals, University of Oxford, Oxford, United Kingdom.

Owen B Spiller (OB)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.

Lizzie Stafford (L)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Craig P Thompson (CP)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Lance Turtle (L)

Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.

Ellie Barnes (E)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom.

Susanna Dunachie (S)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom.

Miles Carroll (M)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom.

Paul Klenerman (P)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom.

Chris Conlon (C)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Philip Goulder (P)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Lucy C Jones (LC)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH